OncoMatch/Colorectal Cancer (CRC)/MLH1
Colorectal Cancer (CRC)MLH1 Clinical Trials
MLH1 promoter hypermethylation — the most common cause of sporadic dMMR CRC — silences MLH1 expression in approximately 10–15% of colorectal cancers and confers MSI-H status. MLH1/PMS2 co-loss is the typical IHC pattern for sporadic dMMR, predicting response to checkpoint immunotherapy. Pembrolizumab monotherapy is the first-line standard of care for MLH1-deficient/dMMR metastatic CRC.
Top recruiting MLH1 Colorectal Cancer (CRC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Sun Yat-sen University
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
Sixth Affiliated Hospital, Sun Yat-sen University
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
National Cancer Institute, Naples
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Criterium, Inc.
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
BioNTech SE
More MLH1 Colorectal Cancer (CRC) trials
14 international trials (no US sites)
Browse other molecular targets with active Colorectal Cancer (CRC) trials.